Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
